Autoimmune Cytopenia(s) might be initial presentation of Primary Immunodeficiency and Immune
Dysregulation Disorder
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Introduction

•Primary immunodeficiency is a common diagnosis
among patients with autoimmune cytopenia.
Autoimmunity and immune dysregulation causing
immune cytopenias might be an initial presentation in
some patients.
•Here we describe 2 patients with autoimmune
cytopenias and one them was eventually diagnosed
with ALPS (Autoimmune lymphoproliferative
syndrome) and the other with CVID( Common variable
immunodeficiency).
•ALPS is characterized by dysregulation of the immune
system due to inability to regulate lymphocyte
homeostasis through the process of lymphocyte
apoptosis. Autoimmunity is a common feature and is
typically limited to the hematopoietic system but can
involve other organs such as liver and kidneys.
Combinations of cytopenias that occur concomitantly
or /and sequentially are typically with Coomb’s positive
autoimmune hemolytic anemia and ITP.
•CVID is a primary immunodeficiency characterized by
impaired B cell differentiation or function with
defective immunoglobulin production. Autoimmune
cytopenias are a more common presenting disorder in
children than adults and maybe the initial
manifestation. ITP and hemolytic anemia or
combinations of these disorders were present in 33% of
pediatric onset CVID patients with evidence of
autoimmunity.

Case

•Patient 1: 19y/o female who was admitted 4 years ago
with severe anemia. Work up showed H/H 6.7/19, retic
8%. Antibody screen positive, warm, and cold
autoantibodies, Mycoplasma IgG and IgM were positive.
She was diagnosed with autoimmune hemolytic anemia.
She had 4 recurrences and was treated with systemic
steroids with a positive response. No history of recurrent
infections but had chronic lymphopenia off steroids.
Immune work up showed low CD4, increased double
negative T-cells (17%). Genetic testing for ALPS was
negative but she met criteria for ALPS type3. She was
started on Sirolimus 6mo ago and is maintaining a stable
hemoglobin.
•Patient 2: 15y/o male with chronic refractory ITP, who
also had history of AIHA, achieved remission after a
course of IVIG at age 5. At age 9, he was diagnosed with
ITP. He was treated with steroids, IVIG and rituximab
over the course of 2 years. He remained in remission for
3 years but recently developed chronic ITP. Immunology
work up revealed very low IgG and IgA, low naïve T cells,
significantly decreased class switched memory B cells
and absent plasmablasts. He had the classical findings of
common variable immunodeficiency and was started on
IgG replacement therapy and sirolimus, after the
completion of short steroid course for chronic ITP.

Discussion
•Patient 1 was diagnosed due to a history of recurrent
episodes of autoimmune hemolytic anemia and chronic
lymphopenia even off steroids.
•Patient 2 was diagnosed due to sequential cytopenias
and evidence of hypogammaglobulinemia
•Both patients were initially treated with steroids but with
the confirmed diagnoses they were started on sirolimus
•They have been able to maintain stable and normal
counts on this steroid sparing therapy without significant
side effects.

•Patients with a history of chronic or multilineage
immune cytopenias should be investigated further for
autoimmune disorders or an underlying immune
deficiency/immune dysregulation. Immunoglobulin
substitution and steroid sparing therapy are
fundamental in these patients. Early diagnosis may
reduce treatment failure, morbidity, mortality, and
long-term steroid therapy associated adverse effects.
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